ATARA Biotherapeutics (ATRA) Tops Q3 EPS by 4c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.90), $0.04 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $3.92 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• HSBC Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)